Press coverage about Proteon Therapeutics (NASDAQ:PRTO) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteon Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.5761960438751 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of research firms have weighed in on PRTO. HC Wainwright set a $3.00 price target on Proteon Therapeutics and gave the company a “hold” rating in a research note on Saturday, May 13th. Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Proteon Therapeutics in a research note on Wednesday. Cowen and Company restated a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday, August 8th. Zacks Investment Research downgraded Proteon Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Maxim Group set a $6.00 price target on Proteon Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 4th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $8.00.
Shares of Proteon Therapeutics (NASDAQ PRTO) traded up 3.85% on Friday, hitting $1.35. The stock had a trading volume of 16,557 shares. The company has a 50-day moving average of $1.37 and a 200 day moving average of $1.52. Proteon Therapeutics has a 52 week low of $1.10 and a 52 week high of $11.45. The company’s market capitalization is $23.79 million.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
What are top analysts saying about Proteon Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Proteon Therapeutics Inc. and related companies.